Sonoma Pharmaceuticals (SNOA) Gains from Investment Securities (2010 - 2025)
Sonoma Pharmaceuticals (SNOA) recorded quarterly Gains from Investment Securities of $2918.0 in Q4 2025, up 1174.24% quarter-over-quarter from $229.0 in Q3 2025, and up 1067.2% on a YoY basis from $250.0 in Q4 2024.
Sonoma Pharmaceuticals (SNOA) Gains from Investment Securities (2010 - 2025) Analysis & Trends
Sonoma Pharmaceuticals' Gains from Investment Securities history runs 16 years deep, the most recent figure standing at $2918.0 for Q4 2025.
- In Q4 2025, Gains from Investment Securities rose 1067.2% year-over-year to $2918.0; the TTM figure through Dec 2025 stood at $2918.0 (up 1067.2% YoY), while the FY2025 annual figure was $73081.0, up 41.42% from the prior year.
- Gains from Investment Securities was $2918.0 for Q4 2025 at Sonoma Pharmaceuticals, up from $229.0 in the prior quarter.
- In the past five years, Gains from Investment Securities ranged from a high of $992999.0 in Q2 2024 to a low of $229.0 in Q3 2025.
- Historically, Gains from Investment Securities has averaged $237907.4 across 5 years, with a median of $64040.5 in 2022.
- The sharpest annual moves came in 2022 and 2024: Gains from Investment Securities soared 11495.94% in 2022, then slumped 99.95% in 2024.
- A 5-year view of Gains from Investment Securities shows it stood at $3500.0 in 2021, then surged by 16344.17% to $575546.0 in 2022, then slipped by 13.13% to $500000.0 in 2023, then plunged by 99.95% to $250.0 in 2024, then soared by 1067.2% to $2918.0 in 2025.
- The last three Gains from Investment Securities figures came in at $2918.0 (Q4 2025), $229.0 (Q3 2025), and $9000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn |
| 10 | Sonoma Pharmaceuticals | 1.87 Mn | -693,829.94 | 1.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2,918.00 |
| Dec 31, 2025 | 2,918.00 |
| Sep 30, 2025 | 229.00 |
| Sep 30, 2025 | 229.00 |
| Jun 30, 2025 | 9,000.00 |
| Jun 30, 2025 | 9,000.00 |
| Mar 31, 2025 | 73,081.00 |
| Mar 31, 2025 | 73,081.00 |
| Dec 31, 2024 | 250.00 |
| Dec 31, 2024 | 250.00 |
| Sep 30, 2024 | 250.00 |
| Sep 30, 2024 | 250.00 |
| Jun 30, 2024 | 992,999.00 |
| Jun 30, 2024 | 992,999.00 |
| Mar 31, 2024 | 51,675.00 |
| Mar 31, 2024 | 51,675.00 |
| Dec 31, 2023 | 500,000.00 |
| Dec 31, 2023 | 500,000.00 |
| Sep 30, 2023 | 244,000.00 |
| Sep 30, 2023 | 244,000.00 |